5-HT2 receptor-mediated reversal of the inhibition of hippocampal long-term potentiation by acute inescapable stress.
The serotonergic system is known to modulate and mediate many of the central nervous system effects of stress. Here we investigated the ability of serotonergic agents to reverse the inhibition of the induction of hippocampal long-term potentiation (LTP) caused by prior exposure to inescapable stress. Elevated platform stress prevented the induction of LTP in the CA1 area of anaesthetized rats. An agent that increases extracellular 5-HT concentration, fenfluramine (5 mg/kg, i.p.) enabled the induction of LTP in previously stressed animals. Consistent with a role for enhanced activation of 5-HT(2) receptors, the facilitatory effect of fenfluramine was prevented by the 5-HT(2) receptor antagonist cinanserin (30 mg/kg). Agents that directly activate 5-HT(2) receptors, including the 5-HT(2B) receptor agonist BW 723C86 (30 mg/kg) and the 5-HT(2C) receptor agonist MK-212 (3 mg/kg), mimicked the restorative effect of fenfluramine. Fenfluramine also opposed inhibition of LTP caused by the NMDA-receptor antagonist D-AP5 (100 nmol, i.c.v.) which suggests that the facilitatory action of serotonergic agents is not restricted to stress-mediated inhibition of LTP. These findings support an important role for activation of 5-HT(2) receptors by systemically applied agents to enable recovery from the inhibition of LTP by stress.
Department of Pharmacology and Therapeutics, Biotechnology Building, Trinity College, Dublin 2, Ireland.
Benedict K
BK
Ryan
Roger
R
Anwyl
Michael J
MJ
Rowan
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D002928:Cinanserin / Q000494:pharmacology; D004195:Disease Models, Animal; D004307:Dose-Response Relationship, Radiation; D004333:Drug Administration Routes; D004347:Drug Interactions; D004558:Electric Stimulation; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005277:Fenfluramine / Q000494:pharmacology; D006624:Hippocampus / Q000503:physiopathology*; D007211:Indoles / Q000494:pharmacology; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D008297:Male; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D044348:Receptors, Serotonin, 5-HT2 / Q000502:physiology*; D012149:Restraint, Physical / Q000379:methods; D018490:Serotonin Agents / Q000494:pharmacology; D013315:Stress, Psychological / Q000209:etiology / Q000473:pathology*; D013876:Thiophenes / Q000494:pharmacology
C092430:1-(5-(2-thenyloxy)-1H-indol-3-yl)propan-2-amine; D018691:Excitatory Amino Acid Antagonists; D007211:Indoles; D044348:Receptors, Serotonin, 5-HT2; D018490:Serotonin Agents; D013876:Thiophenes; D005277:Fenfluramine; D015763:2-Amino-5-phosphonovalerate; D002928:Cinanserin